Doxil is administered at an initial rate of 1 mg/min to minimize the risk of infusion reactions. If no infusion related reactions occur, the rate of infusion can be increased to complete administration over 1 hour. Under no circumstances should the medication be administered as a bolus injection or undiluted solution.
Dosages for various types of cancer are as follows:
• Ovarian cancer after failure of platinum based chemotherapy: 50 mg/m2 IV every 4 weeks
• AIDS-related Kaposi’s Sarcoma after failure of prior systemic chemotherapy or intolerance to such therapy: 20 mg/m2 IV every 3 weeks
• Multiple Myeloma, in combination with bortezomib in patients who have not previously received bortezomib and have received at least one prior therapy: 30 mg/m2 IV on day 4 following bortezomib
Dosages for various types of cancer are as follows:
• Ovarian cancer after failure of platinum based chemotherapy: 50 mg/m2 IV every 4 weeks
• AIDS-related Kaposi’s Sarcoma after failure of prior systemic chemotherapy or intolerance to such therapy: 20 mg/m2 IV every 3 weeks
• Multiple Myeloma, in combination with bortezomib in patients who have not previously received bortezomib and have received at least one prior therapy: 30 mg/m2 IV on day 4 following bortezomib